Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z. +16 more·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1607751

Cited by (1,433)

Items 201–300 of 1,433

Update on the role of lenalidomide in patients with multiple myeloma
Sarah A. Holstein, Vera Jean Suman, Philip L. McCarthy · 2018 · Therapeutic Advances in Hematology
Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
Ioannis V. Kostopoulos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Ourania Tsitsilonis, Evangelos Terpos · 2020 · Frontiers in Oncology
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
María‐Victoria Mateos, Meletios Athanasios Dimopoulos, Michèle Cavo, Kenshi Suzuki, Stefan Tobias Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Sebastian Grosicki et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Laurens E. Franssen, Claudia A.M. Stege, Sonja Zweegman, Niels W.C.J. van de Donk, Inger S. Nijhof · 2020 · Journal of Clinical Medicine
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
Anjan Thakurta, William E. Pierceall, Michael D. Amatangelo, Erin Flynt, Amit Agarwal · 2021 · Oncotarget
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Kitsada Wudhikarn, Beatriz Wills, Alexander M. Lesokhin · 2020 · Best Practice & Research Clinical Haematology
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
Yoichi Imai, Mitsuhito Hirano, Masayuki Kobayashi, Muneyoshi Futami, Arinobu Tojo · 2019 · Cancers
How I manage the toxicities of myeloma drugs
Michel Delforge, Heinz Ludwig · 2017 · Blood
Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany
Monika Martha Engelhardt, Gabriele Ihorst, Moushmi Singh · 2020 · Clinical Lymphoma Myeloma & Leukemia
Daratumumab proves safe and highly effective in AL amyloidosis
Jack Khouri, Andrew Daniel Kin, Bicky Thapa et al. · 2018 · British Journal of Haematology
Treatment of relapsed multiple myeloma: Evidence-based recommendations
Ceren Durer, Seren Durer, Sarah Lee, Rajshekhar Chakraborty, Mustafa Nadeem Malik, Abdul Rafae, Muhammad Abu Zar, Ahmad Kamal, Nathaniel Rosko, Christy Joy Samaras et al. · 2019 · Blood Reviews
Additivity predicts the efficacy of most approved combination therapies for advanced cancer
Haeun Hwangbo, Sarah C. Patterson, Andy Dai, Deborah Plana, Adam Christopher Palmer · 2023 · Nature Cancer
Current Treatment Strategies for Multiple Myeloma
Andrew Robert Branagan, Matthew M. Lei, Uvette Y. Lou, Noopur S Raje · 2020 · JCO Oncology Practice
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Danai Dima, Joshua Dower, Raymond L. Comenzo, Cindy Varga · 2020 · Cancer Management and Research
The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages
Dimitrios Mougiakakos, Christian Bach, Martin Böttcher, Fabian Beier, Linda Röhner, Andrej Stoll, Michael Rehli, Claudia Gebhard, Christopher Lischer, Martin Eberhardt et al. · 2021 · Cancer Immunology Research
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma
Julia Bluhm, Elisa Kieback, Stephen F. Marino, Felix Oden, Jörg Westermann, Markus Martin Chmielewski, Hinrich Abken, Wolfgang Uckert, Uta E. Höpken, Armin Rehm · 2018 · Molecular Therapy
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
María‐Victoria Mateos, Andrew G Spencer, Ajay K. Nooka et al. · 2019 · Haematologica
The emerging therapeutic landscape of relapsed/refractory multiple myeloma
Benjamin Tanenbaum, Timothy Miett, Shyam Ajay Patel · 2022 · Annals of Hematology
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Avirup Guha, Merna A. Armanious, Michael G. Fradley · 2018 · Trends in Cardiovascular Medicine
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
D'Souza, Criselle, Prince, H. Miles, Neeson, Paul J. · 2021 · Frontiers in Immunology
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
Jessica S Little, Zoe Weiss, Sarah Page Hammond · 2021 · Journal of Fungi
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Amrita Y. Krishnan, Prashant Kapoor, Joycelynne Michelle Palmer, Ni‐Chun Tsai, Shaji Kunnathu Kumar, Sagar Lonial, Myo Htut, Chatchada Karanes, Nitya Nathwani, Michael Alan Rosenzweig et al. · 2018 · Leukemia
Current use of monoclonal antibodies in the treatment of multiple myeloma
Cindy Varga, Michelle E. Maglio, Irene M. Ghobrial, Paul Gerard Guy Richardson · 2018 · British Journal of Haematology
Clinical impact of the CONUT score in patients with multiple myeloma
Sho Okamoto, Hiroshi Ureshino, Keisuke Kidoguchi, Kana Kusaba, Haruna Kizuka-Sano, Haruhiko Sano, Atsujiro Nishioka, Kyosuke Yamaguchi, Kazuharu Kamachi, Hidekazu Itamura et al. · 2019 · Annals of Hematology
CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Federica Costa, Benedetta Dalla Palma, Nicola Giuliani · 2019 · Cells
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States
Josh John Carlson, Gregory F. Guzauskas, Richard H. Chapman, Patricia G. Synnott, Shanshan Liu, Elizabeth T. Russo, Steven D. Pearson, Elizabeth Brouwer, Daniel A. Ollendorf · 2017 · Journal of Managed Care & Specialty Pharmacy
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function
Paolo Milani, Marco Basset, Paola Curci et al. · 2020 · Blood Advances
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy
Frank Bridoux, Bertrand Arnulf, Lionel Karlin, Nicolas Blin, Nolwenn Rabot, Margaret Macro, Vincent Audard, Karim Belhadj, Brigitte Pegourié, Pierre Gobert et al. · 2020 · Journal of Clinical Oncology
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
on behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group, Paula Arana, Bruno Paiva, M.‐T. Cedena, Noemí Puig, Lourdes Cordón, María‐Belén Vídriales, Norma Carmen Gutierrez, F Chiodi, Leire Burgos et al. · 2017 · Leukemia
CD38 as an immunotherapeutic target in multiple myeloma
Francesca Bonello, Mattia D’Agostino, Maria Moscvin, Chiara Cerrato, Mario Boccadoro, Francesca Gay · 2018 · Expert Opinion on Biological Therapy
Chemotherapy and Beyond
Sarah Atkins, Fiona C. He · 2019 · Infectious Disease Clinics of North America
Treatment of relapsed and refractory multiple myeloma
Ji Hyun Lee, Sung‐Hyun Kim · 2020 · Blood Research
Risk of infection associated with targeted therapies for solid organ and hematological malignancies
Isabel Ruíz-Camps · 2021 · Therapeutic Advances in Infectious Disease
The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma
Susanne Schmitz, Áine Maguire, James Morris, Kai Ruggeri, Elisa Haller, Isla L. Kuhn, Joy Leahy, Natalia Homer, Ayesha Khan, Jack Bowden et al. · 2018 · BMC Medical Research Methodology
Insights on Multiple Myeloma Treatment Strategies
María‐Victoria Mateos, Heinz Ludwig, Ali A. Bazarbachi, Meral Beksaç, Joan Bladé, Mario Boccadoro, Michèle Cavo, Michel Delforge, Meletios Athanasios Dimopoulos, Thierry T.F. Facon et al. · 2018 · HemaSphere
How I treat relapsed multiple myeloma
Efstathios Kastritis, Evangelos Terpos, Meletios Athanasios Dimopoulos · 2022 · Blood
New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
Paola E. Neri, Nizar Jacques Bahlis, Sagar Lonial · 2016 · Clinical Cancer Research
New Agents in Multiple Myeloma: An Examination of Safety Profiles
Sara Bringhen, Edwin de Wit, Meletios Athanasios Dimopoulos · 2017 · Clinical Lymphoma Myeloma & Leukemia
Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma
Felicia Tang, Ehsan Malek, Susan Math, Christine L. Schmotzer, Rose C Beck · 2018 · American Journal of Clinical Pathology
Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis
Rajshekhar Chakraborty, Irbaz Bin Riaz, Saad Ullah Malik, Naimisha Marneni, Alex Mejia Garcia, Faiz Anwer, Alok A. Khorana, S. Vincent Rajkumar, Shaji Kunnathu Kumar, Mohammad Hassan Murad et al. · 2020 · Cancer
Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab
Amrita Y. Krishnan, Vikram Adhikarla, Erasmus Kofi Poku, Joycelynne Michelle Palmer, Ammar Ahmed Chaudhry, Van Eric Biglang-awa, Nicole Bowles, Nitya Nathwani, Michael Alan Rosenzweig, Firoozeh Sahebi et al. · 2020 · Blood Advances
A novel circRNA-miRNA-mRNA network revealed exosomal circ-ATP10A as a biomarker for multiple myeloma angiogenesis
Manya Yu, Jie Yu, Yanyu Zhang, Xiaoqi Sun, Runjie Sun, Mengting Xia, Sumei Li, Xing Cui · 2021 · Bioengineered · Retracted
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
Anja Seckinger, Jens Hillengaß, Martina Emde, Susanne Beck, Christoph Richard Kimmich, Tobias Dittrich, Michael Hundemer, Anna Sophia Jauch, Ute Hegenbart, Marc‐Steffen Raab et al. · 2018 · Frontiers in Immunology
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
Klara Kropivšek, Paul Kachel, Sandra Götze, Rebekka Wegmann, Yasmin Festl, Yannik Severin, Benjamin D. Hale, Julien Mena, Audrey van Drogen, Nadja Dietliker et al. · 2023 · Nature Cancer
Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors
Tomáš Jelı́nek, David Žihala, T. Sevcikova, Anjana Anilkumar Sithara, Veronika Kapustová, Hana Sahinbegovic, Ondrej Venglár, Ludmila Muroňová, Lucie Broskevičová, Serafim Nenarokov et al. · 2024 · Leukemia
Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma
Xavier P Leleu, Tamás Masszi, Nizar Jacques Bahlis, Luísa Viterbo, Bartrum Baker, Peter Gimsing, Vladimír Maisnar, Olga S. Samoilova, Laura Rosiñol, Christian Langer et al. · 2018 · American Journal of Hematology
Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
Siegel, David S., Schiller, Gary J., Song, Kevin W., Agajanian, Richy, Stockerl‐Goldstein, Keith, Kaya, Hakan, Sebag, Michael, Samaras, Christy, Malek, Ehsan, Talamo, Giampaolo et al. · 2020 · British Journal of Haematology
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
Francesca Bonello, Roberto Mina, Mario Boccadoro, Francesca Gay · 2019 · Cancers
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kelly, Kevin R, Ailawadhi, Sikander, Siegel, David S, Heffner, Leonard T, Somlo, George, Jagannath, Sundar, Zimmerman, Todd M, Munshi, Nikhil C, Madan, Sumit, Chanan-Khan, Asher et al. · 2021 · The Lancet Haematology
How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
Pieter Sonneveld, Edwin de Wit, Philippe Moreau · 2017 · Critical Reviews in Oncology/Hematology
Daratumumab for the treatment of multiple myeloma
Cyrille Touzeau, Philippe Moreau · 2017 · Expert Opinion on Biological Therapy
Emerging drugs and combinations to treat multiple myeloma
Alessandra Larocca, Roberto Mina, Francesca Gay, Sara Bringhen, Mario Boccadoro · 2017 · Oncotarget
The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma
Agne Paner, Pritesh Rajni Patel, Binod Dhakal · 2019 · Blood Reviews
Daratumumab in untreated newly diagnosed multiple myeloma
Nadine H. Abdallah, Shaji Kunnathu Kumar · 2019 · Therapeutic Advances in Hematology
Immunotherapies for pediatric cancer: current landscape and future perspectives
Hutzen, Brian, Paudel, Siddhi Nath, Naeimi Kararoudi, Meisam, Cassady, Kevin A., Lee, Dean A., Cripe, Timothy P. · 2019 · Cancer and Metastasis Reviews
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Luciano J. Costa, Yi Lin, Robert Frank Cornell, Thomas G. Martin, Saurabh Chhabra, Saad Z. Usmani, Sundar Jagannath, Natalie S. Callander, Jesús G. Berdeja, Yubin Kang et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Qian Shi, Bruno Paiva, Levi Pederson, Natalie Dimier, Ela Talpes, Thomas J. Prior, Alberto Órfão, Philippe Moreau, Pieter Sonneveld, Shaji Kunnathu Kumar et al. · 2025 · Journal of Clinical Oncology
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions
Philippe Moreau, Edwin de Wit · 2017 · British Journal of Haematology
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway
Leonhard Busch, Dimitrios Mougiakakos, Maike J. Büttner-Herold, Miriam J. Müller, Dietrich A. Volmer, Christian Bach, Mario Fabri, Joerg Thomas Bittenbring, Frank Neumann, Rainer Boxhammer et al. · 2018 · Leukemia
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Meletios Athanasios Dimopoulos, Michael L. Wang, Vladimír Maisnar, Jiří Minařík, William Bensinger, María‐Victoria Mateos, Mihaela Obreja, Julie Blædel, Philippe Moreau · 2018 · Journal of Hematology & Oncology
How I treat the young patient with multiple myeloma
Sara Gandolfi, Claudia Paba Prada, Paul Gerard Guy Richardson · 2018 · Blood
Infectious and immunological sequelae of daratumumab in multiple myeloma
Andrew J. Johnsrud, Joyce J. Johnsrud, Sandra P. Susanibar-Adaniya, Jorge Jo Kamimoto, Atul Kothari, Mary Burgess, Frits van Rhee, Juan Carlos Rico · 2018 · British Journal of Haematology
Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
Noémie Leblay, Ranjan Maity, Fajer Hasan, Paola E. Neri · 2020 · Frontiers in Oncology
Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma
Saeko Kuwahara‐Ota, Yuji Shimura, Christian Steinebach, Reiko Isa, Junko Yamaguchi, Daichi Nishiyama, Yuto Fujibayashi, Tomoko Takimoto‐Shimomura, Yoshimi Mizuno, Yayoi Matsumura‐Kimoto et al. · 2020 · British Journal of Haematology
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Jakub Radocha, Niels W.C.J. van de Donk, Katja Christina Weisel · 2021 · Cancers
Immunotherapy in Multiple Myeloma
Cinnie Yentia Soekojo, Melissa Gaik Ming Ooi, Sanjay De Mel, Wee Joo Chng · 2020 · Cells
New agents in the Treatment of Myeloma Bone Disease
Elizabeth S. Ring, Michelle Anne Lawson, John Andrew Snowden, Ingrid Jolley, Andrew Chantry · 2017 · Calcified Tissue International
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Jacob P. Laubach, Chia‐Jen Liu, Noopur S Raje, Andrew Jenho Yee, Philippe A. Armand, Robert L Schlossman, Jacalyn M. Rosenblatt, Jacquelyn Ann Hedlund, Michael Gary Martin, Craig H. Reynolds et al. · 2018 · Clinical Cancer Research
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients
Akihiro Kitadate, Hiroki Kobayashi, Yoshiaki Abe · 2019 · Haematologica
Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
Cippitelli, Marco, Stabile, Helena, Kosta, Andrea, Petillo, Sara, Gismondi, Angela, Santoni, Angela, Fionda, Cinzia · 2021 · International Journal of Molecular Sciences
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
Massimo Offidani, Laura Corvatta, Sonia Morè, Attilio Olivieri · 2021 · Drug Design Development and Therapy
Progress in Myeloma — A Monoclonal Breakthrough
Rajkumar, S. Vincent, Kyle, Robert A. · 2016 · New England Journal of Medicine
Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis
Stephanos Vassilopoulos, Athanasios Vassilopoulos, Markos Kalligeros, Fadi Shehadeh, Eleftherios E Mylonakis · 2022 · Open Forum Infectious Diseases
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma
Tiantian Zhang, Sen Wang, Teng-Fei Lin, Jingmei Xie, Lina Zhao, Zhuoru Liang, Yangqiu Li, Jie Jiang · 2017 · Oncotarget
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
Rafael Ríos, Martin-Garcia Agustin, Carolina Alarcón-Payer, Sánchez-Rodríguez Dolores, Valle Díaz de la Guardia Ana María, Carlos García Collado, Jimenez Morales Alberto, Jurado Chacon Manuel, José Cabeza Barrera · 2017 · Drug Design Development and Therapy
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab
Ajay K. Nooka, Charise L. Gleason, Marva Ollivierre Sargeant, Michelle Walker, Melanie Watson, Elyse Hall Panjic, Sagar Lonial · 2018 · Journal of Oncology Practice
New Drugs in Multiple Myeloma
Chutima Kunacheewa, Robert Zygmunt Orlowski · 2019 · Annual Review of Medicine
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Nina D. Shah, Jack Aiello, David Avigan, Jesús G. Berdeja, Ivan Borrello, Ajai Chari, Adam D. Cohen, Karthik A. Ganapathi, Lissa Gray, Damian J. Green et al. · 2020 · Journal for ImmunoTherapy of Cancer
Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, Chang Gon Kim, Haerim Chung, Yoon Seok Choi, Su‐Hyung Park, June‐Won Cheong, Yoo Hong Min, Eui‐Cheol Shin et al. · 2021 · Clinical Cancer Research
HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers
Nizar Joher, Marie Matignon, Philippe Grimbert · 2021 · Frontiers in Immunology
Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma
Kristine A. Frerichs, Monique C. Minnema, Mark‐David Levin, Annemiek Broijl, Gerard M.J. Bos, Marie José Kersten, Tuna Mutis, Christie P.M. Verkleij, Inger S. Nijhof, Patricia W. C. Maas-Bosman et al. · 2021 · Blood Advances
Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update
Arjun Lakshman, Shaji Kunnathu Kumar · 2021 · American Journal of Hematology
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
Hiroko Nishida, Mutsumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada · 2018 · Blood Cancer Journal
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors
Francesca Gay, Mattia D’Agostino, Luisa Giaccone, Mariella Genuardi, Moreno Benedetto Festuccia, Mario Boccadoro, Benedetto Bruno · 2017 · Clinical Lymphoma Myeloma & Leukemia
Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma
Ajai Chari, Suzanne A. Arinsburg, Sundar Jagannath, Toshihisa Satta, Ivey Treadwell, Donna Catamero, Gillian Morgan, Huaibao Feng, Clarissa Uhlar, Imran Khan et al. · 2017 · Clinical Lymphoma Myeloma & Leukemia
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
Kristine A. Frerichs, Noemi Anna Nagy, Pieter L. Lindenbergh, Patty Bosman, Jhon A. Marin Soto, Marloes E.C. Broekmans, Richard W.J. Groen, Maria Themeli, Louise Nieuwenhuis, Claudia A.M. Stege et al. · 2018 · Expert Review of Clinical Immunology
Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma
Hang Quach, Simon Benson, Helen E Haysom et al. · 2018 · Internal Medicine Journal
Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma
Boyu Hu, Yasuhiro Oki · 2018 · Frontiers in Oncology
Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain
Malik Bechakra, Mariska D. Nieuwenhoff, Joost van Rosmalen · 2018 · Molecular Pain
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Gilles A. Salles, Ajay K. Gopal, Monique C. Minnema, Karen Wakamiya, Huaibao Feng, Jordan Mark Schecter, Michael L. Wang · 2019 · Clinical Lymphoma Myeloma & Leukemia
New generation drugs for treatment of multiple myeloma
Fehaid Ghali Alanazi, Faith A. A. Kwa, Genia Burchall, Denise E. Jackson · 2019 · Drug Discovery Today
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
Evangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, Jiří Minařík, Ioannis Ntanasis‐Stathopoulos, Eirini Katodritou, Matthew W. Jenner, Hana Plonková, Maria Gavriatopoulou, Grant D. Vallance et al. · 2020 · Annals of Hematology
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
Olivia Perez de Acha, Lauren T. Reiman, David S. Jayabalan, Zachary J. Walker, Grace Bosma, Alana L. Keller, Sarah E. Parzych, Diana Abbott, Beau M. Idler, Drew Ribadeneyra et al. · 2023 · Blood Advances
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari, Sagar Lonial, Tomer Martin Mark, Amrita Y. Krishnan, Keith E Stockerl-Goldstein, Saad Z. Usmani, Anil Londhe, Delores Etheredge, Sarah Fleming, Baolian Liu et al. · 2018 · Cancer
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
Shih‐Feng Cho, Lijie Xing, Kenneth Carl Anderson, Yu‐Tzu Tai · 2021 · Cancers
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
José‐Ángel Hernández‐Rivas, Rafael Ríos, Cristina Encinas, Rafael Alonso, Juan José Lahuerta · 2022 · Biomarker Research
The evolution of stem-cell transplantation in multiple myeloma
Sarakshi Mahajan, Nidhi Tandon, Shaji Kunnathu Kumar · 2018 · Therapeutic Advances in Hematology
Integration of Novel Agents into the Care of Patients with Multiple Myeloma
Robert Zygmunt Orlowski, Sagar Lonial · 2016 · Clinical Cancer Research
The Anti-CD38 Antibody Therapy in Multiple Myeloma
Maria Teresa Petrucci, Federico Vozella · 2019 · Cells
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
Cristina Gasparetto, Suzanne Lentzsch, Gary John Schiller, Natalie S. Callander, Sascha Alexander Tuchman, Christine I. Chen, Darrell J. White, Rami R. Kotb, Heather J. Sutherland, Michaël Sébag et al. · 2020 · eJHaem